These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 29164377

  • 1. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).
    Barton DL, Shuster LT, Dockter T, Atherton PJ, Thielen J, Birrell SN, Sood R, Griffin P, Terstriep SA, Mattar B, Lafky JM, Loprinzi CL.
    Support Care Cancer; 2018 Apr; 26(4):1335-1343. PubMed ID: 29164377
    [Abstract] [Full Text] [Related]

  • 2. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance).
    Barton DL, Sloan JA, Shuster LT, Gill P, Griffin P, Flynn K, Terstriep SA, Rana FN, Dockter T, Atherton PJ, Tsai M, Sturtz K, Lafky JM, Riepl M, Thielen J, Loprinzi CL.
    Support Care Cancer; 2018 Feb; 26(2):643-650. PubMed ID: 28921241
    [Abstract] [Full Text] [Related]

  • 3. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur É, other participating members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [Abstract] [Full Text] [Related]

  • 4. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA.
    Ke Y, Gonthier R, Simard JN, Archer D, Lavoie L, Martel C, Vaillancourt M, Labrie F.
    Horm Mol Biol Clin Investig; 2015 Dec; 24(3):117-29. PubMed ID: 26509785
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women.
    Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C.
    J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):178-94. PubMed ID: 18598765
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
    Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, Members of the VVA Prasterone Research Group.
    J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
    [Abstract] [Full Text] [Related]

  • 11. Effects of a 3-week dehydroepiandrosterone administration on sleep, sex steroids and multiple 24-h hormonal profiles in postmenopausal women: a pilot study.
    Caufriez A, Leproult R, L'Hermite-Balériaux M, Kerkhofs M, Copinschi G.
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):716-24. PubMed ID: 23488643
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
    Baumgart J, Nilsson K, Stavreus Evers A, Kunovac Kallak T, Kushnir MM, Bergquist J, Sundström Poromaa I.
    Climacteric; 2014 Feb; 17(1):48-54. PubMed ID: 23647561
    [Abstract] [Full Text] [Related]

  • 14. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS.
    JAMA Oncol; 2017 Mar 01; 3(3):313-319. PubMed ID: 27832260
    [Abstract] [Full Text] [Related]

  • 15. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
    Panjari M, Davis SR.
    Maturitas; 2011 Sep 01; 70(1):22-5. PubMed ID: 21733647
    [Abstract] [Full Text] [Related]

  • 16. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
    Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dubé R, other participating members of VVA Prasterone Group.
    Menopause; 2015 Dec 01; 22(12):1289-95. PubMed ID: 25968836
    [Abstract] [Full Text] [Related]

  • 17. Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors.
    Kallak TK, Baumgart J, Göransson E, Nilsson K, Poromaa IS, Stavreus-Evers A.
    Menopause; 2014 Apr 01; 21(4):383-90. PubMed ID: 24080848
    [Abstract] [Full Text] [Related]

  • 18. Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer.
    Johansson H, Bonanni B, Mariette F, Cazzaniga M, Baglietto L, Guerrieri-Gonzaga A, Sandri MT, Luini A, Pelosi G, Decensi A.
    Breast Cancer Res Treat; 2006 Jul 01; 98(2):167-72. PubMed ID: 16538534
    [Abstract] [Full Text] [Related]

  • 19. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quirós JR, Roddam A, Thiebaut A, Tjønneland A, Chirlaque MD, Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, Riboli E.
    J Natl Cancer Inst; 2005 May 18; 97(10):755-65. PubMed ID: 15900045
    [Abstract] [Full Text] [Related]

  • 20. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K, Neuenschwander PF, Kurdowska AK.
    Int J Pharm Compd; 2013 May 18; 17(1):74-85. PubMed ID: 23627249
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.